Levebon (Levetiracetam)

Levetiracetam binds to the synaptic vesicle protein SV2A, a key regulator of neurotransmitter release. This binding modulates synaptic transmission, decreasing neuronal hyperexcitability and thereby lowering the likelihood of seizure initiation.

The dosage of Levebon is individualized by a qualified prescriber based on the patient’s age, weight, renal function, and seizure type. The prescribing clinician determines the appropriate starting dose and any necessary adjustments.

The safety of levetiracetam in pregnancy and lactation has not been definitively established. Healthcare providers weigh the potential benefits for seizure control against any possible risks to the fetus or infant before prescribing.

To request Levebon, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Levebon (levetiracetam) offers a distinct mechanism by targeting SV2A, which differs from sodium‑channel blockers like carbamazepine or GABA‑enhancers such as valproate. It is generally well‑tolerated, has fewer drug‑enzyme interactions, and is often chosen when rapid titration or minimal hepatic metabolism is desired.

Levebon should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the tablets from moisture, excessive heat, and direct sunlight to maintain stability and potency.

Levebon is taken orally, usually as a tablet, with or without food. Patients should follow the prescribing clinician’s instructions regarding timing and whether the dose should be split or taken whole.

Serious adverse events, though uncommon, include severe allergic reactions, Stevens‑Johnson syndrome, toxic epidermal necrolysis, and psychiatric effects such as depression or suicidal thoughts. Any sudden mood changes or skin eruptions should be reported to a healthcare professional immediately.

Levebon is contraindicated in patients with known hypersensitivity to levetiracetam or any of its excipients. Caution is advised for individuals with severe renal impairment, uncontrolled psychiatric conditions, or those who are pregnant without a clear benefit‑risk assessment.